Monte Rosa Therapeutics Inc Quick Ratio (GLUE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Monte Rosa Therapeutics Inc   (NASDAQ: GLUE)

Monte Rosa Therapeutics Inc 's Quick Ratio

GLUE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Monte Rosa Therapeutics Inc 's Cash & cash equivalent grew by 72.93 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Monte Rosa Therapeutics Inc 's Quick Ratio to 8.32, Quick Ratio remained below Monte Rosa Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Quick Ratio than Monte Rosa Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 735, from total ranking in the first quarter 2026 at 1276.

Explain Quick Ratio?
How much Cash & cash equivalents GLUE´s has?
What are GLUE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLUE Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 231.04 % 88.35 % -34.63 % 203.55 % -1.17 %
Y / Y Cash & cash equivalent Change 296.46 % 104.32 % 1.33 % 61.55 % 10.83 %
Quick Ratio MRQ 8.32 5.97 3.28 3.1 6.94
GLUE's Total Ranking # 735 # 1276 # 1210 # 700 # 843
Seq. Current Liabilities Change 24.22 % -2.91 % -9.11 % 202.02 % -29.32 %
Seq. Cash & cash equivalent Change 72.93 % 76.67 % -3.62 % 34.64 % -10.88 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 198
Overall Market # 554


Quick Ratio Statistics
High Average Low
33.09 11.03 2.12
(Jun 30 2021)   (Dec 31 2024)




Financial Statements
Monte Rosa Therapeutics Inc 's Current Liabilities $ 139 Millions Visit GLUE's Balance sheet
Monte Rosa Therapeutics Inc 's Cash & cash equivalent $ 1,152 Millions Visit GLUE's Balance sheet
Source of GLUE's Sales Visit GLUE's Sales by Geography


Cumulative Monte Rosa Therapeutics Inc 's Quick Ratio

GLUE's Quick Ratio for the trailling 12 Months

GLUE Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 54.3 % 23.75 % 13.73 % 134.59 % 108.35 %
Y / Y Cash & cash equivalent TTM Growth 110.13 % 43.45 % 29.51 % 48.44 % 42.15 %
Quick Ratio TTM 5.26 4.37 4.05 3.42 3.87
Total Ranking TTM # 986 # 1132 # 789 # 739 # 692
Seq. Current Liabilities TTM Growth 24.5 % 15.28 % -15.09 % 26.62 % -0.16 %
Seq. Cash & cash equivalent TTM Growth 49.94 % 24.56 % 0.36 % 12.11 % 2.36 %

Quick ratio ranking by company, industry and sector >> Back to GLUE Financial Strength Comparisons >> Go to Compare GLUE Quick Ratio to its Competitors

On the trailing twelve months basis GLUE Cash & cash equivalent more than doubled by 296.46 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Monte Rosa Therapeutics Inc 's Quick Ratio to 5.26, Quick Ratio remained below GLUE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Monte Rosa Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2732.

Explain Quick Ratio?
How much Cash & cash equivalents GLUE´s has?
What are GLUE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 874
Within the Market # 735


trailing twelve months Quick Ratio Statistics
High Average Low
22.95 5.49 1.42
(Mar 31 2022)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Cg Oncology Inc   21.77 $ 1,028.278  Millions$ 47.240  Millions
Instil Bio Inc   21.08 $ 69.678  Millions$ 3.305  Millions
Solid Biosciences Inc   20.85 $ 595.984  Millions$ 28.584  Millions
Relay Therapeutics Inc   17.93 $ 910.934  Millions$ 50.804  Millions
Maze Therapeutics Inc   17.90 $ 411.087  Millions$ 22.961  Millions
Crispr Therapeutics Ag  17.79 $ 2,364.352  Millions$ 132.896  Millions
Taysha Gene Therapies Inc   17.53 $ 455.407  Millions$ 25.975  Millions
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions

Date modified: 2026-09-08T17:53:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.